GLP-1 Hub Podcast
GLP-1 Access: What to Do When Coverage and Cost Get in the Way
Amanda Bonello explains how repeated coverage denials led to patient advocacy, with practical questions about appeals, assistance and reliable care.
Listen to this episode
The GLP-1 Hub Podcast
Seven prior-authorization attempts, and still no covered GLP-1. That is the experience Amanda Bonello describes to Ana Reisdorf: her doctor supported treatment, but her insurance did not cover the options her care team tried. The problem was not simply finding a prescription.
Bonello, founder of the GLP-1 Collective, turned that frustration into a petition, a podcast and patient advocacy. Her story explains why access involves more than a drug’s advertised price. It also helps separate two different jobs: making a workable plan for your own care and asking for broader changes in affordability and coverage.
A prescription, insurance coverage and affordability are different hurdles
Bonello recalls calling her insurer to ask which GLP-1 it preferred for obesity and being told it had none. She then worked with a telehealth team that submitted multiple prior authorizations. In her account, all were denied. The clinician’s willingness to prescribe did not change the benefit available through her plan.
That distinction is useful when you hear that someone else obtained the same medicine. Their diagnosis, benefit design, requirements or assistance eligibility may differ. A lower advertised cash price may still be beyond your budget, while an insured person’s copay can remain difficult to pay.
Before another application, ask for the actual reason for the denial. Is a required document missing? Is the medicine outside the formulary? Does the plan exclude treatment for the intended use? Those questions can help your care team decide what to investigate next. They do not guarantee that an excluded benefit will become covered.
Turn a denial into a specific next conversation
Keep the denial notice, the relevant plan documents, the medicine and indication being considered, and a record of whom you contacted. Ask the insurer which review or exception process applies and what deadline and supporting information it requires. Share that answer with the prescribing office so repeated requests address the stated problem.
HealthCare.gov explains internal appeals and independent external review. The available route depends on the plan and decision. CMS describes the scope of the federal external-review process, including qualifying decisions involving medical judgment. An appeal is a process for reviewing a decision, not a promise that every GLP-1 denial can be overturned.
If a refill may be interrupted, contact the prescriber while the coverage question is being worked out. Ask for a medically appropriate contingency plan, including what to do if treatment is delayed. Social-media advice about stretching doses, restarting after a gap or switching products cannot account for your clinical situation.
Gretchen Zimmermann’s discussion of GLP-1 costs and equitable care offers a companion perspective on the support that needs to accompany access.
Assistance programs solve particular problems
Bonello is excited in the interview about a newly announced obesity copay-assistance program. She also notices its limitation: assistance with a covered medicine’s copay does not solve the same problem as having no insurance or having a plan that excludes the treatment.
The PAN Foundation’s July 2025 announcement required insurance covering a qualifying medication and other eligibility criteria. Its current site directs assistance inquiries to TotalAssist following the 2026 merger with Patient Advocate Foundation. The historical announcement is not confirmation that a fund is open or that you qualify today.
When checking any program, ask what expense it helps with, which medicines and insurance situations qualify, whether income rules apply, whether applications are currently open, and how long any support lasts. Ask the program directly before counting that help toward your medication budget.
Bonello also discusses a hoped-for assistance program for uninsured people. That was a plan at the time of the conversation. The Collective’s current mission page explicitly says its medication-payment program never launched and describes its present education, navigation resources and advocacy. It should not be treated as an active medication fund or a prescribing service.
What a patient story can achieve, and what it cannot
Bonello says her petition brought media interviews and helped her build a platform where people could describe their experiences. She wanted listeners to see the people behind arguments about drug prices: people managing symptoms, worrying about losing treatment and trying to understand their options.
She is also candid about the limits. At the time of the interview, many people she had contacted had not responded. Public attention and a large letter did not mean a regulator had changed a rule or an insurer had approved a prescription.
If you choose to share an access story, make the problem concrete: what barrier occurred, what steps you tried, and what change would help. A clear account of a missing benefit or an unaffordable copay communicates more than assuming everyone faces the same obstacle. Share only the personal and medical details you are comfortable making public.
For an organization or campaign, check its current purpose and who receives a payment before donating or promoting an initiative. Bonello explains that money spent promoting her petition through its hosting platform did not go to the nonprofit. Supporting visibility and funding patient assistance are different transactions.
Kim Carlos’s conversation about how GLP-1 patients became advocates explores the related work of turning personal experience into a public voice.
Access pressure does not make an unknown product reliable
Ana describes the anxiety of pharmacy problems and another prior-authorization request. Bonello recognizes why people become desperate when treatment feels uncertain. That empathy is central to the conversation; it does not establish that a product offered in a comment thread is safe.
The FDA warns about unapproved GLP-1 products, dosing errors and products falsely sold for research purposes. It advises obtaining a prescription from a doctor and using a state-licensed pharmacy. Compounded drugs do not undergo FDA approval for safety, effectiveness and quality, and a social-media seller’s claims cannot supply that review.
Bring the access problem to your clinical team rather than treating an unverified seller as a substitute for a care plan. Advocacy can acknowledge the pressure people face while still demanding reliable medicines and appropriate follow-up.
Start with the barrier you can name
Bonello’s experience shows how quickly an individual coverage problem can become a larger question about who gets care. Her persistence built connections and made patient stories easier to hear. It did not remove every financial or administrative hurdle.
For your next step, identify what is blocking access, gather the written information behind it, and decide who can address that particular issue. Your prescriber, insurer, an assistance program and an advocacy organization have different roles. Knowing which conversation you need can make the work ahead more focused, even when the answer takes time.
